A UAE longevity and functional-medicine clinic group that publicly advertises clinician-led peptide protocols.
Availability does not establish approval or effectiveness. Ask for the exact active ingredient, product registration, indication, prescriber, dispensing source, risks, alternatives, and follow-up plan.
The clinic names these compounds on its own service page. Several are experimental or lack established approval for the promoted uses; listing them does not establish safety, efficacy, or UAE product registration.
No peptide-specific price list was found on DNA Health's public peptide page.
Prices published for other DNA Health services are not treated as peptide-treatment prices.
Price information is attributed to the clinic and may change. It does not establish medical approval, product registration, effectiveness or the total cost of care.
These labels assess the named molecule, not the clinic’s particular product, protocol or marketing claim. UAE registration remains product and indication specific.
| Peptide | Category | Evidence | Approval note | Editorial assessment |
|---|---|---|---|---|
| AOD-9604 | Experimental compound | Limited | Not established for broad weight-loss use | Early research does not establish the broad weight-management outcomes frequently used in marketing. |
| BPC-157 | Experimental compound | Preclinical | Not established as an approved human medicine | Most supportive claims rely on laboratory or animal research; robust clinical evidence and established approval are lacking. |
| CJC-1295 | Experimental compound | Limited | Not established as an approved human medicine | Small human studies do not establish broad wellness, anti-ageing or body-composition claims. |
| Epitalon | Experimental compound | Limited | Not established as an approved human medicine | Longevity claims are not supported by robust, independently replicated clinical evidence. |
| GHK-Cu | Experimental compound | Limited | Depends on formulation and intended use | Cosmetic ingredient use is different from injected or systemic treatment claims. Evidence and regulation depend on formulation. |
| Ipamorelin | Experimental compound | Limited | Not established as an approved human medicine | Human evidence is limited and does not establish the broad outcomes commonly promoted by clinics. |
| Kisspeptin | Experimental compound | Limited | Specialist or investigational context | Human research exists in reproductive endocrinology, but routine commercial wellness use is not established. |
| MOTS-c | Experimental compound | Preclinical | Not established as an approved human medicine | Metabolic and longevity claims remain predominantly experimental and are not established clinical outcomes. |
| PT-141 | Prescription medicine | Moderate | Exact product and indication specific | Related prescription products exist in some jurisdictions for a narrow indication; clinic formulations and UAE status must be checked. |
| Thymosin Alpha-1 | Experimental compound | Limited | Jurisdiction and indication specific | Research exists in selected conditions, but broad immune or wellness claims are not established by that evidence. |
| Thymosin Beta-4 | Experimental compound | Limited | Exact product and use require verification | Research on thymosin beta-4 should not be treated as evidence for every product marketed as TB-500 or for broad recovery claims. |
8:30am–8:00pm, daily
+971 4 573 65009:00am–10:00pm, daily
+971 4 573 65008:30am–8:00pm, daily
+971 4 573 65009:00am–6:00pm, Monday–Saturday
+971 4 573 65009:00am–8:00pm, daily
+971 4 573 6500Compare clinical assessment, product traceability, informed consent, monitoring, adverse-event support, and alternatives—not marketing claims.
Is this information outdated? Send the editorial team a correction.Clinics cannot pay to change directory order or evidence classifications.